Samalin Ludovic, Charpeaud Thomas, Blanc Olivier, Heres Stephan, Llorca Pierre-Michel
Department of Psychiatry B, University of Auvergne, Clermont-Ferrand, France.
J Nerv Ment Dis. 2013 Jul;201(7):553-9. doi: 10.1097/NMD.0b013e31829829c4.
Depot formulations are not widely used in everyday practice. This study aimed to assess psychiatrists' attitudes toward the use of long-acting injectable (LAI) antipsychotics in schizophrenia. We interviewed 113 French psychiatrists about the factors that influenced their prescription of LAI antipsychotics. Multidimensional and cluster analyses were used to detect correlations. The most important factor against the use of LAI antipsychotics is a sufficient estimated compliance with the oral formulation. For first-generation LAI, the main factor is the risk for extrapyramidal symptoms; and for second-generation LAI, it is the unavailability of the equivalent oral formulation. Four factors incite the psychiatrists to prescribe LAI. Two different clusters of patients can also be identified. Most factors influencing the clinicians' attitudes toward the use of LAI antipsychotics are shared in many countries. Conversely, some attitudes related to organizational aspects, particularly the relevance of health care costs, may vary from one country to another.
长效注射剂剂型在日常临床实践中并未得到广泛应用。本研究旨在评估精神科医生对长效注射用抗精神病药物治疗精神分裂症的态度。我们就影响其长效注射用抗精神病药物处方的因素对113名法国精神科医生进行了访谈。采用多维度分析和聚类分析来检测相关性。反对使用长效注射用抗精神病药物的最重要因素是预计患者对口服制剂有足够的依从性。对于第一代长效注射剂，主要因素是锥体外系症状的风险；而对于第二代长效注射剂，主要因素是等效口服制剂难以获得。有四个因素促使精神科医生开具长效注射剂。还可识别出两类不同的患者群体。许多国家影响临床医生对长效注射用抗精神病药物使用态度的大多数因素是相同的。相反，一些与组织方面相关的态度，尤其是医疗保健成本的相关性，可能因国家而异。
